Prostate biopsy

From Wikipedia, the free encyclopedia
Prostate biopsy
Diagram showing a transperineal prostate biopsy

Prostate biopsy is a procedure in which small hollow needle-core samples are removed from a man's prostate gland to be examined for the presence of prostate cancer. It is typically performed when the result from a PSA blood test is high.[1] It may also be considered advisable after a digital rectal exam (DRE) finds possible abnormality. PSA screening is controversial as PSA may become elevated due to non-cancerous conditions such as benign prostatic hyperplasia (BPH), by infection, or by manipulation of the prostate during surgery or catheterization. Additionally many prostate cancers detected by screening develop so slowly that they would not cause problems during a man's lifetime, making the complications due to treatment unnecessary.

The most frequent side effect of the procedure is blood in the urine (31%).[2] Other side effects may include infection (0.9%) and death (0.2%).[2]

Ultrasound-guided prostate biopsy[edit]

The procedure may be performed transrectally, through the urethra or through the perineum. The most common approach is transrectally, and historically this was done with tactile finger guidance.[3] The most common method of prostate biopsy as of 2014 was transrectal ultrasound-guided prostate (TRUS) biopsy.[4]

Extended biopsy schemes take 12 to 14 cores from the prostate gland through a thin needle in a systematic fashion from different regions of the prostate.[5]

A biopsy procedure with a higher rate of cancer detection is template prostate mapping (TPM) or transperineal template-guided mapping biopsy (TTMB), whereby typically 50 to 60 samples are taken of the prostate through the outer skin between the rectum and scrotum, to thoroughly sample and map the entire prostate, through a template with holes every 5mm, usually under a general or spinal anaesthetic.[6][7]

Antibiotics are usually prescribed to minimize the risk of infection.[4][8] A healthcare provider may also prescribe an enema to be taken in the morning of the procedure. During the transrectal procedure, an ultrasound probe is inserted into the rectum to assist in guiding the biopsy needles. Following this, a local anesthetic, such as anesthetic, is administered into the tissue surrounding the prostate. Subsequently, a spring-loaded biopsy needle is inserted into the prostate, resulting in a clicking sound. When the local anesthetic is effective, any discomfort experienced is minimal.

MRI-guided targeted biopsy[edit]

MRI-US fusion biopsy
3d-reconstructed prostate gland indicating suspicious lesions for targeted biopsy.

Since the mid-1980s, TRUS biopsy has been used to diagnose prostate cancer in essentially a blind fashion because prostate cancer cannot be seen on ultrasound due to poor soft tissue resolution. However, multi-parametric magnetic resonance imaging (mpMRI) has since about 2005 been used to better identify and characterize prostate cancer.[9] A study correlating MRI and surgical pathology specimens demonstrated a sensitivity of 59% and specificity of 84% in identifying cancer when T2-weighted, dynamic contrast enhanced, and diffusion-weighted imaging were used together.[10] Many prostate cancers missed by conventional biopsy are detectable by MRI-guided targeted biopsy.[11] In fact, a side-by-side comparison of TRUS versus MRI-guided targeted biopsy that was conducted as a prospective, investigator-blinded study demonstrated that MRI-guided biopsy improved detection of significant prostate cancer by 17.7%, and decreased the diagnosis of insignificant or low-risk disease by 89.4%.[12]

Two methods of MRI-guided, or "targeted" prostate biopsy, are available: (1) direct "in-bore" biopsy within the MRI tube, and (2) fusion biopsy using a device that fuses stored MRI with real-time ultrasound (MRI-US). Visual or cognitive MRI-US fusion have been described.[13]

When MRI is used alone to guide prostate biopsy, it is done by an interventional radiologist. Correlation between biopsy and final pathology is improved between MRI-guided biopsy as compared to TRUS.[14]

In the fusion MRI-US prostate biopsy, a prostate MRI is performed before biopsy and then, at the time of biopsy, the MRI images are fused to the ultrasound images to guide the urologist to the suspicious targets. Fusion MRI-US biopsies can be achieved in an office setting with a variety of devices.[11]

MRI-guided prostate biopsy appears to be superior to standard TRUS-biopsy in prostate cancer detection. Several groups in the U.S.,[15][16] and Europe,[17][18] have demonstrated that targeted biopsies obtained with fusion imaging are more likely to reveal cancer than blind systematic biopsies. In 2015, AdMeTech Foundation, American College of Radiology and European Society of Eurogenital Radiology developed Prostate Imaging Reporting and Data System (PI-RADS v2) for global standardization of image acquisition and interpretation, which similarly to BI-RADS standardization of breast imaging, is expected to improve patient selection for biopsies and precisely-targeted tissue sampling.[19][20] PI-RADS v2 created standards for optimal mpMRI image reporting and graded the level of suspicion based on the score of one to five, with the goal to improve early detection (and exclusion) of clinically significant (or aggressive) prostate cancer.[21] The higher suspicion on mpMRI and the higher PI-RADS v2 score, the greater the likelihood of aggressive prostate cancer on targeted biopsy. Considerable experience and training is required by the reader of prostate mpMRI studies.

Up to 2013, indications for targeted biopsy have included mainly patients for whom traditional TRUS biopsies have been negative despite concern for rising PSA, as well as for patients enrolling in a program of active surveillance who may benefit from a confirmatory biopsy and/or the added confidence of more accurate non-invasive monitoring.[15] Increasingly, men undergoing initial biopsy are requesting targeted biopsy, and thus, the use of pre-biopsy MRI is growing rapidly.

Clinical trials of mpMRI and PI-RADS v2, including NIH-funded studies are underway to further clarify the benefits of targeted prostate biopsy.[22]

Side effects[edit]

Side effects of a TRUS or TPM biopsy include:[23][6][24]

  • rectal pain or discomfort (very common)
  • burning when passing urine (very common)
  • bruising (very common with TPM only)
  • bloody urine for 2–3 days (very common)
  • bloody semen for ~3 months (30% with TRUS; ~100% with TPM)
  • poor erections for ~8 weeks (30% with TRUS; ~100% with TPM)
  • infection of skin or urine (1-8%)
  • infection of skin or urine requiring hospitalisation and intravenous antibiotics (1-4%)
  • difficulty urinating (1% with TRUS; >5% with TPM)

Gleason score[edit]

The tissue samples are examined under a microscope to determine whether cancer cells are present, and to evaluate the microscopic features (or Gleason score) of any cancer found. Gleason score, PSA, and digital rectal examination together determine clinical risk, which then dictates treatment options.

Tumor markers[edit]

Tissue samples can be stained for the presence of PSA and other tumor markers in order to determine the origin of malignant cells that have metastasized.[25]


  1. ^ Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. (September 2018). "Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis". BMJ. 362: k3519. doi:10.1136/bmj.k3519. PMC 6283370. PMID 30185521.
  2. ^ a b Bell N, Connor Gorber S, Shane A, Joffres M, Singh H, Dickinson J, et al. (November 2014). "Recommendations on screening for prostate cancer with the prostate-specific antigen test". CMAJ. 186 (16): 1225–34. doi:10.1503/cmaj.140703. PMC 4216256. PMID 25349003.
  3. ^ Ghei M, Pericleous S, Kumar A, Miller R, Nathan S, Maraj BH (September 2005). "Finger-guided transrectal biopsy of the prostate: a modified, safer technique". Annals of the Royal College of Surgeons of England. 87 (5): 386–7. PMC 1963966. PMID 16402467.
  4. ^ a b Roberts MJ, Bennett HY, Harris PN, Holmes M, Grummet J, Naber K, Wagenlehner FM (June 2017). "Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches" (PDF). Urology. 104: 11–21. doi:10.1016/j.urology.2016.12.011. PMID 28007492.
  5. ^ Patel AR, Jones JS (May 2009). "Optimal biopsy strategies for the diagnosis and staging of prostate cancer". Current Opinion in Urology. 19 (3): 232–7. doi:10.1097/MOU.0b013e328329a33e. PMID 19365892.
  6. ^ a b PROMIS - Prostate MRI Imaging Study. An evaluation of multi-parametric magnetic resonance imaging in the diagnosis and characterisation of prostate cancer. (UK) Medical Research Council - Clinical Trials Unit - PROMIS Trials Office. MRC: PR11, 2 February 2012
  7. ^ Taira AV, Merrick GS, Galbreath RW, Andreini H, Taubenslag W, Curtis R, et al. (March 2010). "Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting". Prostate Cancer and Prostatic Diseases. 13 (1): 71–7. doi:10.1038/pcan.2009.42. PMC 2834351. PMID 19786982.
  8. ^ Yaghi MD, Kehinde EO (2015). "Oral antibiotics in trans-rectal prostate biopsy and its efficacy to reduce infectious complications: Systematic review". Urology Annals. 7 (4): 417–27. doi:10.4103/0974-7796.164860. PMC 4660689. PMID 26538868.
  9. ^ Bonekamp D, Jacobs MA, El-Khouli R, Stoianovici D, Macura KJ (May–June 2011). "Advancements in MR imaging of the prostate: from diagnosis to interventions". Radiographics. 31 (3): 677–703. doi:10.1148/rg.313105139. PMC 3093638. PMID 21571651.
  10. ^ Isebaert S, Van den Bergh L, Haustermans K, Joniau S, Lerut E, De Wever L, et al. (June 2013). "Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology". Journal of Magnetic Resonance Imaging. 37 (6): 1392–401. doi:10.1002/jmri.23938. PMID 23172614.
  11. ^ a b Marks L, Young S, Natarajan S (January 2013). "MRI-ultrasound fusion for guidance of targeted prostate biopsy". Current Opinion in Urology. 23 (1): 43–50. doi:10.1097/MOU.0b013e32835ad3ee. PMC 3581822. PMID 23138468.
  12. ^ Pokorny MR, de Rooij M, Duncan E, Schröder FH, Parkinson R, Barentsz JO, Thompson LC (July 2014). "Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies". European Urology. 66 (1): 22–9. doi:10.1016/j.eururo.2014.03.002. PMID 24666839.
  13. ^ Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Fütterer JJ, Gill IS, et al. (October 2013). "Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group". European Urology. 64 (4): 544–52. doi:10.1016/j.eururo.2013.03.030. PMID 23537686.
  14. ^ Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, Scheenen T, Fütterer J, Bouwense S, et al. (January 2012). "Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort". European Urology. 61 (1): 177–84. doi:10.1016/j.eururo.2011.08.042. hdl:2066/109206. PMID 21924545.
  15. ^ a b Sonn GA, Natarajan S, Margolis DJ, MacAiran M, Lieu P, Huang J, et al. (January 2013). "Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device". The Journal of Urology. 189 (1): 86–91. doi:10.1016/j.juro.2012.08.095. PMC 3561472. PMID 23158413.
  16. ^ Vourganti S, Rastinehad A, Yerram N, Nix J, Volkin D, Hoang A, et al. (December 2012). "Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies". The Journal of Urology. 188 (6): 2152–2157. doi:10.1016/j.juro.2012.08.025. PMC 3895467. PMID 23083875.
  17. ^ Kuru TH, Roethke MC, Seidenader J, Simpfendörfer T, Boxler S, Alammar K, et al. (October 2013). "Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer". The Journal of Urology. 190 (4): 1380–6. doi:10.1016/j.juro.2013.04.043. PMID 23608676.
  18. ^ Fiard G, Hohn N, Descotes JL, Rambeaud JJ, Troccaz J, Long JA (June 2013). "Targeted MRI-guided prostate biopsies for the detection of prostate cancer: initial clinical experience with real-time 3-dimensional transrectal ultrasound guidance and magnetic resonance/transrectal ultrasound image fusion". Urology. 81 (6): 1372–8. doi:10.1016/j.urology.2013.02.022. PMID 23540865.
  19. ^ "AdMeTech". Retrieved 2015-09-28.
  20. ^ "Prostate Imaging Reporting and Data System (PI-RADS) - American College of Radiology". Retrieved 2015-09-28.
  21. ^ Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. (January 2016). "PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2". European Urology. 69 (1): 16–40. doi:10.1016/j.eururo.2015.08.052. PMC 6467207. PMID 26427566.
  22. ^ "Search of: prostate mri biopsy - List Results -".
  23. ^ Roberts MJ, Bennett HY, Harris PN, Holmes M, Grummet J, Naber K, Wagenlehner FM (June 2017). "Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches" (PDF). Urology. 104: 11–21. doi:10.1016/j.urology.2016.12.011. PMID 28007492.
  24. ^ "Five Tips for a Safe Endocavity Biopsy". EDM Medical Solutions. 21 September 2018.
  25. ^ Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI (August 2007). "Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma". The American Journal of Surgical Pathology. 31 (8): 1246–55. doi:10.1097/PAS.0b013e31802f5d33. PMID 17667550. S2CID 11535862.